{"classes":[{"categories":[{"measurements":[{"comment":"Upper end confidence interval is not estimable because the number of events beyond the median, and their timing, does not permit calculation of the upper confidence interval.","groupId":"OG000","lowerLimit":"10.2","upperLimit":"NA","value":"13.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"MEDIAN","populationDescription":"One participant declined to participate before treatment started.","reportingStatus":"POSTED","timeFrame":"The participants were followed for a median of 15.4 years.","title":"Median Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"years"}